Agents targeting these pathways, including tyrosinase inhibitors such as arbutin and kojic acid, and depigmenting agents like azelaic acid, have shown efficacy in managing melasma [4,14,15] Personalizing treatment based on the patient’s genetic profile may enhance therapeutic outcomes. The gene discussed is TYR; the disease is freckles.